The manufacture of DC vaccines mainly begins with the isolation of monocytes, CD34+ hematopoietic stem cells (HSC), and myeloid leukemic blasts to obtain imDCs or leukemia-derived DCs (DCleu) by adding granulocyte colony-stimulating factor- macrophages (GM-CSF) plus IL-4 or Prostaglandin E1 (PGE1) and Fms-related receptor tyrosine kinase 3 ligand (Flt3L), respectively. The gene discussed is FLT3LG; the disease is leukemia.